{"id":10368,"date":"2026-02-17T12:38:23","date_gmt":"2026-02-17T12:38:23","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/10368\/"},"modified":"2026-02-17T12:38:23","modified_gmt":"2026-02-17T12:38:23","slug":"roche-to-acquire-89bio-for-2-4-billion-in-liver-and-cardiometabolic-push-roche-holding-otcrhhby","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/10368\/","title":{"rendered":"Roche To Acquire 89bio For $2.4 Billion In Liver And Cardiometabolic Push – Roche Holding (OTC:RHHBY)"},"content":{"rendered":"

On Thursday, Roche Holdings AG (OTC:RHHBY<\/a>) agreed to acquire 89bio, Inc. (NASDAQ:ETNB<\/a>) for $2.4 billion. 89Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for liver and cardiometabolic diseases<\/a>.<\/p>\n

Roche will acquire the company for $14.50 per share, representing a premium of approximately 79% to 89bio\u2019s closing stock price on September 17, 2025, the last trading day before the announcement of the transaction, and a premium of 52% to 89bio\u2019s 60-day volume-weighted average price<\/a>.<\/p>\n

In addition, 89bio stockholders will receive a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $6.00 per share in cash upon achievement of specified milestones, for a total transaction equity value of up to approximately $3.5 billion on a fully diluted basis.<\/p>\n

Also Read: New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data<\/a><\/p>\n

89bio\u2019s pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients (F2 and F3 stages) as well as cirrhotic patients (F4 stage)<\/a>.<\/p>\n

Acquiring 89bio, therefore, fosters Roche\u2019s activities to build a robust and differentiated pipeline that targets additional causes of metabolic disease.<\/p>\n

\u201cWith its combined anti-fibrotic and anti-inflammatory mechanism, pegozafermin could potentially offer best-in-disease efficacy for all moderate to severe MASH patients,\u201d said Thomas Schinecker, Roche Group CEO<\/a>.<\/p>\n

Each non-tradeable CVR will entitle its holders to receive the following contingent cash payments:<\/p>\n

$2.00 per share in cash, upon the first commercial sale of pegozafermin in F4 MASH cirrhotic patients (by March 31, 2030)<\/p>\n

$1.50 per share in cash, upon pegozafermin reaching annual net sales globally of at least US $3.0 billion in any calendar year (by December 31, 2033)<\/p>\n

$2.50 per share in cash, upon pegozafermin reaching annual net sales globally of at least US $4.0 billion in any calendar year (by December 31, 2035).<\/p>\n

The transaction is currently expected to close in the fourth quarter of 2025.<\/p>\n

Price Action: ENTB stock is up 85.15% at $14.97\u00a0at the last check on Thursday.<\/p>\n

Read Next:<\/p>\n

Photo: Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"On Thursday, Roche Holdings AG (OTC:RHHBY) agreed to acquire 89bio, Inc. (NASDAQ:ETNB) for $2.4 billion. 89Bio is a…\n","protected":false},"author":2,"featured_media":10369,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[342,1016,344,914,346,1328,343,920,341,340,134,8046,347,1335],"class_list":{"0":"post-10368","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-category-biotech","9":"tag-category-general","10":"tag-category-health-care","11":"tag-category-large-cap","12":"tag-category-movers","13":"tag-category-mu0026a","14":"tag-category-news","15":"tag-category-trading-ideas","16":"tag-cms-wordpress","17":"tag-pageisbzpro-bz","18":"tag-roche","19":"tag-symbol-etnb","20":"tag-symbol-rhhby","21":"tag-tag-why-its-moving"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/10368","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=10368"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/10368\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/10369"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=10368"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=10368"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=10368"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}